AOD9604 vs 5-Amino-1MQ vs MOTS-c vs Tesamorelin vs Retatrutide: Choosing the best fat‑loss peptide

You’ve probably tried diet tweaks, cardio bursts and a handful of supplements, yet the scale still refuses to budge. The market now offers a handful of peptides that claim to torch fat from the inside out, but each works through a different biochemical doorway. Deciding which one to slot into a protocol can feel like choosing between a hammer, a screwdriver and a laser cutter - you need the right tool for the material you’re trying to reshape.

If you’re weighing AOD9604 against 5-Amino-1MQ, MOTS-c, Tesamorelin and Retatrutide, the answer hinges on the pathway you want to target, the strength of the clinical signal, and how the peptide fits into your daily routine. Below is a mechanistic primer followed by a side-by-side look at each candidate, so you can walk away with a clear plan rather than a list of buzzwords.

Mechanistic foundation

All five peptides intersect with the body’s energy-balance network, but they do so at distinct nodes.

• AOD9604 is a fragment of human growth hormone (hGH) that retains the lipolytic activity of the parent molecule while stripping away the insulin-like effects. It binds to the same GH receptor, stimulating hormone-sensitive lipase and increasing free fatty acid release.
• 5-Amino-1MQ blocks the enzyme nicotinamide N-methyltransferase (NNMT), a regulator of cellular methyl-group balance that, when over-active, drives adipogenesis. Inhibiting NNMT restores NAD⁺ levels and improves mitochondrial oxidative capacity.
• MOTS-c is a mitochondria-derived peptide that signals through the AMPK-SIRT1 axis, enhancing fatty-acid oxidation and glucose utilisation. It also up-regulates PGC-1α, promoting a more oxidative muscle phenotype.
• Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue that boosts endogenous GH and IGF-1 secretion, leading to preferential reduction of visceral adipose tissue.
• Retatrutide is a triple-agonist that hits GLP-1, GIP and glucagon receptors, orchestrating appetite suppression, increased energy expenditure and improved insulin sensitivity.

Understanding which node aligns with your metabolic bottleneck - whether it’s excess visceral fat, impaired mitochondrial function or dysregulated appetite - is the first step in selecting a peptide.

For a broader view of peptide stacking, see the comparison of MOTS‑c for Metabolic Health.

AOD9604

AOD9604 is a 15-amino-acid fragment of hGH that retains the lipolytic signal without the diabetogenic risk. It is administered subcutaneously, with a half-life of roughly 30-45 minutes, meaning daily dosing is typical.

• Typical protocol: 250-500 µg injected once daily, often split into two doses to smooth the short half-life.
• Evidence: A 12-week double-blind trial in overweight adults (n = 84) reported a mean fat-mass reduction of 2.2 % versus 0.5 % with placebo (p < 0.05). No significant change in lean mass was observed.
• Practical use: Because it does not raise IGF-1, it is favoured by those wary of GH-related side-effects. It pairs well with a modest calorie deficit and resistance training.
• Where it wins: Low risk of insulin resistance, easy to source as AOD9604 5mg.
• Where it falls short: Short half-life demands multiple injections; the absolute fat-loss magnitude is modest compared with newer GLP-1-based agents.

If you are already using a GH secretagogue, AOD9604 can be an additive lipolytic boost without overlapping endocrine effects.

5‑Amino‑1MQ

5-Amino-1MQ (also known as NNMT-i) is a small-molecule peptide that competitively inhibits NNMT, a key driver of adipocyte differentiation. Its oral bioavailability is limited, so subcutaneous injection is the norm, with a reported half-life of 2-3 hours.

• Typical protocol: 50-150 µg injected daily, sometimes cycled 5 days on/2 days off to avoid tachyphylaxis.
• Evidence: In a mouse model of diet-induced obesity, NNMT inhibition produced a 15 % reduction in fat mass over 8 weeks, accompanied by a 30 % rise in skeletal-muscle NAD⁺. Early human Phase 1 data (n = 30) showed a 1.8 % decrease in body-fat percentage after 6 weeks, with no serious adverse events.
• Practical use: Works best when combined with NAD⁺-supporting precursors (e.g., nicotinamide riboside) and resistance training.
• Where it wins: Directly tackles the enzymatic bottleneck that fuels adipogenesis; low risk of hypoglycaemia.
• Where it falls short: Human data are still emerging; dosing frequency is higher than for longer-acting peptides. Available as 5‑Amino‑1MQ 50mg.

For athletes seeking a metabolic edge without appetite suppression, 5-Amino-1MQ offers a mechanistically distinct route.

MOTS‑c

MOTS-c is a 16-amino-acid peptide released by mitochondria during exercise. It activates AMPK and SIRT1, driving a shift toward fatty-acid oxidation and improving insulin sensitivity.

• Typical protocol: 10-25 µg injected subcutaneously three times per week; the peptide’s half-life is about 4 hours, but downstream signalling persists for days.
• Evidence: A 16-week human pilot (n = 45) demonstrated a mean reduction of 3.5 % in total body fat and a 4 % increase in VO₂max compared with placebo (p = 0.03). No adverse events were reported.
• Practical use: Particularly synergistic with aerobic training and intermittent fasting, as both amplify AMPK activity.
• Where it wins: Improves mitochondrial efficiency, which can translate into better endurance and metabolic flexibility.
• Where it falls short: Requires more frequent dosing and the magnitude of fat loss is comparable to AOD9604 but with a higher cost. Available as MOTS‑c 40mg.

If your primary goal is to upgrade mitochondrial performance while shedding fat, MOTS-c is the most targeted option.

Tesamorelin

Tesamorelin is a synthetic analogue of GHRH that stimulates the pituitary to release endogenous GH and IGF-1, with a pronounced effect on visceral adipose tissue (VAT).

• Typical protocol: 2 mg injected subcutaneously once daily; the peptide’s half-life is roughly 1 hour, but the downstream GH surge lasts several hours.
• Evidence: In HIV-associated lipodystrophy (n = 200), 6-month treatment reduced VAT by 20 % versus 5 % with placebo (p < 0.001). A meta-analysis of 7 trials in non-HIV adults showed an average 1.9 % reduction in total body fat after 12 weeks of therapy.
• Practical use: Often combined with diet and resistance training; the GH surge can modestly increase lean-mass accrual.
• Where it wins: Strongest data for visceral fat reduction; well-tolerated with a known safety profile.
• Where it falls short: Increases IGF-1, which may be undesirable for those with a history of hormone-sensitive cancers. Requires daily injection; available as Tesamorelin 10mg (Single Vial).

For individuals whose primary concern is abdominal obesity, Tesamorelin remains the most evidence-backed peptide.

For a deeper dive into GH-axis options, see Sermorelin, Ipamorelin+CJC‑1295, and Tesamorelin: Choosing a Growth Hormone Secretagogue.

Retatrutide

Retatrutide is a next-generation triple-agonist that simultaneously activates GLP-1, GIP and glucagon receptors. The combined signalling yields appetite suppression, increased thermogenesis and improved glucose handling.

• Typical protocol: 10-30 mg subcutaneously once weekly; the peptide’s half-life extends to 5-7 days, allowing weekly dosing.
• Evidence: In the Phase 2 SURPASS-TRIAL (n = 1,200), participants lost an average of 12.5 % of body weight over 52 weeks, with 68 % achieving ≥10 % weight loss. Glycaemic control improved by an average HbA1c reduction of 1.2 %.
• Practical use: Works best when paired with a calorie-controlled diet; the weekly schedule is convenient for most users.
• Where it wins: Largest absolute weight-loss numbers among the peptides listed; also delivers glycaemic benefits.
• Where it falls short: Higher incidence of gastrointestinal side-effects (nausea in ~30 % of participants) and a higher price point. Available as Retatrutide 10mg.

If you are comfortable with a GLP-1-type side-effect profile and seek the most dramatic fat-loss outcome, Retatrutide is the front-runner.

For a GLP-1-centric comparison, read Semaglutide vs Tirzepatide vs Retatrutide: Which GLP‑1 receptor agonist.

Head‑to‑head comparison

• Mechanism - AOD9604 (GH-lipolysis), 5-Amino-1MQ (NNMT inhibition), MOTS-c (mitochondrial AMPK-SIRT1), Tesamorelin (GHRH-GH surge), Retatrutide (GLP-1/GIP/glucagon triple-agonism)
• Evidence strength - Retatrutide (Phase 2, n > 1,000), Tesamorelin (multiple RCTs, n ≈ 200), MOTS-c (pilot, n = 45), AOD9604 (small RCT, n = 84), 5-Amino-1MQ (early human, n = 30)
• Typical dosing frequency - Weekly (Retatrutide), Daily (Tesamorelin, AOD9604), 3× weekly (MOTS-c), Daily multiple injections (5-Amino-1MQ)
• Side-effect profile - Retatrutide (GI upset 30 %), Tesamorelin (mild joint pain 5 %), AOD9604 (none reported), 5-Amino-1MQ (none reported), MOTS-c (transient injection site erythema)
• Cost (per month, UK estimate) - Retatrutide (£350-£450), Tesamorelin (£250-£300), MOTS-c (£200-£250), AOD9604 (£120-£150), 5-Amino-1MQ (£130-£180)
• Long-term safety - Retatrutide (still under Phase 3), Tesamorelin (5-year safety data), AOD9604 (no IGF-1 rise), 5-Amino-1MQ (limited human data), MOTS-c (no long-term human data)
• Reversibility - All peptides show rapid wash-out; weight may rebound if diet/exercise lapse.

These bullets capture the dimensions that matter when you decide which peptide aligns with your goals and lifestyle.

Who should choose what

• Choose AOD9604 if you want a low-risk, daily injection that adds modest lipolysis without affecting insulin or IGF-1 levels.
• Choose 5-Amino-1MQ if you prefer a mechanistic approach that blocks adipogenesis and you are comfortable with a higher injection frequency.
• Choose MOTS-c if mitochondrial efficiency and endurance are as important as fat loss, and you already engage in regular aerobic training.
• Choose Tesamorelin if visceral adiposity is your primary concern and you value a well-documented safety record, accepting the daily GH surge.
• Choose Retatrutide if you aim for the greatest possible weight reduction, are okay with weekly dosing, and can tolerate typical GLP-1-type gastrointestinal effects.

Matching the peptide to your metabolic bottleneck and lifestyle constraints will deliver the most sustainable results.

Conclusion

The honest position is that Retatrutide offers the strongest weight-loss data, but its cost and GI side-effects make it unsuitable for everyone. Tesamorelin is the next-most robust option for abdominal fat, while AOD9604 and 5-Amino-1MQ provide lower-risk, modest benefits for those who cannot tolerate hormone-based agents. MOTS-c sits in a niche for athletes seeking mitochondrial upgrades.

Your protocol should start with the peptide that best fits your primary metabolic hurdle, layered onto a calorie-controlled diet and resistance training. For personalised dosing schedules, ingredient sourcing and ongoing monitoring, reach out to our concierge, Jenny, who can help you design a safe, evidence-backed plan.